William Greene
Director Ejecutivo en Iconic Therapeutics, Inc. .
Relaciones activas
Nombre | Sexo | Edad | Empresas relacionadas | Colaboración |
---|---|---|---|---|
Peter Diamandis | M | 62 |
Fountain Therapeutics, Inc.
Fountain Therapeutics, Inc. BiotechnologyHealth Technology Fountain Therapeutics, Inc. develops treatment for aging-associated diseases. The company is headquartered in San Francisco, CA. | 6 años |
Kirk Dornbush | M | - |
Iconic Therapeutics, Inc.
Iconic Therapeutics, Inc. BiotechnologyHealth Technology Iconic Therapeutics, Inc. engages in the development of novel therapeutics for the treatment of serious eye disorders. Its product ICON-1, is a novel immune-conjugate fusion protein that works with the body’s immune system to address the root causes of inflammation and angiogenesis together, potentially altering the course of causes of blindness. The company was founded by Alan Garen, Kirk Dornbush, and Michael I. Sherman in 2003 and is headquartered in South San Francisco, CA. | 21 años |
Thomas Rando | M | - |
Fountain Therapeutics, Inc.
Fountain Therapeutics, Inc. BiotechnologyHealth Technology Fountain Therapeutics, Inc. develops treatment for aging-associated diseases. The company is headquartered in San Francisco, CA. | - |
James Scibetta | M | 59 |
Maverick Therapeutics, Inc.
Maverick Therapeutics, Inc. BiotechnologyHealth Technology Maverick Therapeutics, Inc. operates as a preclinical stage biotech company. It develops a novel class of T cell- redirecting antibody therapeutics that have the potential to substantially broaden the range of targets and clinical applications to be used for this ultra-potent mechanism. The company was founded by Robert Dubridge and Patrick A. Baeuerle in 2016 and is headquartered in Brisbane, CA. | 7 años |
Robert DuBridge | M | - |
Maverick Therapeutics, Inc.
Maverick Therapeutics, Inc. BiotechnologyHealth Technology Maverick Therapeutics, Inc. operates as a preclinical stage biotech company. It develops a novel class of T cell- redirecting antibody therapeutics that have the potential to substantially broaden the range of targets and clinical applications to be used for this ultra-potent mechanism. The company was founded by Robert Dubridge and Patrick A. Baeuerle in 2016 and is headquartered in Brisbane, CA. | 8 años |
Louis Kucera | M | - |
Wake Forest University
| 54 años |
Sangeeta Bhatia | M | 55 |
Maverick Therapeutics, Inc.
Maverick Therapeutics, Inc. BiotechnologyHealth Technology Maverick Therapeutics, Inc. operates as a preclinical stage biotech company. It develops a novel class of T cell- redirecting antibody therapeutics that have the potential to substantially broaden the range of targets and clinical applications to be used for this ultra-potent mechanism. The company was founded by Robert Dubridge and Patrick A. Baeuerle in 2016 and is headquartered in Brisbane, CA. | - |
Michael Batalia | M | - |
Wake Forest University
| - |
Matthew S. Cullinan | M | - |
Wake Forest University
| - |
Darryl L. Landis | M | - |
Wake Forest University
| - |
Stephen R. Berlin | M | - |
Wake Forest University
| - |
Saud Al-Bawardi | M | 48 |
Hevolution Foundation
| - |
Roger Beahm | M | - |
Wake Forest University
| - |
David N. LaMond | M | - |
Wake Forest University
| - |
Detlev Biniszkiewicz | M | 56 |
Maverick Therapeutics, Inc.
Maverick Therapeutics, Inc. BiotechnologyHealth Technology Maverick Therapeutics, Inc. operates as a preclinical stage biotech company. It develops a novel class of T cell- redirecting antibody therapeutics that have the potential to substantially broaden the range of targets and clinical applications to be used for this ultra-potent mechanism. The company was founded by Robert Dubridge and Patrick A. Baeuerle in 2016 and is headquartered in Brisbane, CA. | - |
Yury Kukushkin | M | - |
Hevolution Foundation
| 1 años |
Jane Brightwell | F | - |
Wake Forest University
| - |
Boris Pasche | M | 63 |
Wake Forest University
| - |
Ron Burkle | M | 70 |
Hevolution Foundation
| - |
Khanna Khanna | M | - |
Fountain Therapeutics, Inc.
Fountain Therapeutics, Inc. BiotechnologyHealth Technology Fountain Therapeutics, Inc. develops treatment for aging-associated diseases. The company is headquartered in San Francisco, CA. | - |
Brig Sorber | M | - |
Wake Forest University
| - |
Stan Meiburg | M | - |
Wake Forest University
| - |
Saleh Al-Qahtani | M | - |
Hevolution Foundation
| - |
Munir Eldesouki | M | - |
Hevolution Foundation
| - |
Fahd Al-Rasheed | M | - |
Hevolution Foundation
| - |
Fahad Toonsi | M | - |
Hevolution Foundation
| - |
Yasir Al-Rumayyan | M | - |
Hevolution Foundation
| - |
Mohammed Al-Saud | M | - |
Hevolution Foundation
| - |
Ibrahim AlSuwaiyel | M | - |
Hevolution Foundation
| - |
Martin Guthold | M | - |
Wake Forest University
| - |
Michael Martin | M | - |
Maverick Therapeutics, Inc.
Maverick Therapeutics, Inc. BiotechnologyHealth Technology Maverick Therapeutics, Inc. operates as a preclinical stage biotech company. It develops a novel class of T cell- redirecting antibody therapeutics that have the potential to substantially broaden the range of targets and clinical applications to be used for this ultra-potent mechanism. The company was founded by Robert Dubridge and Patrick A. Baeuerle in 2016 and is headquartered in Brisbane, CA. | - |
Elizabeth Domenech | F | - |
Wake Forest University
| - |
Lisbeth Evans | F | - |
Wake Forest University
| - |
Janice Calloway | F | - |
Wake Forest University
| - |
Louise Broyhill | F | - |
Wake Forest University
| - |
James Becton | M | - |
Wake Forest University
| - |
Greg Keeley | M | - |
Wake Forest University
| - |
Dirk Sauer | M | 64 |
Iconic Therapeutics, Inc.
Iconic Therapeutics, Inc. BiotechnologyHealth Technology Iconic Therapeutics, Inc. engages in the development of novel therapeutics for the treatment of serious eye disorders. Its product ICON-1, is a novel immune-conjugate fusion protein that works with the body’s immune system to address the root causes of inflammation and angiogenesis together, potentially altering the course of causes of blindness. The company was founded by Alan Garen, Kirk Dornbush, and Michael I. Sherman in 2003 and is headquartered in South San Francisco, CA. | 3 años |
Mehmood Khan | M | 66 |
Hevolution Foundation
| 4 años |
Troy McConnell | M | - |
Wake Forest University
| - |
Elizabeth Amato | F | 67 |
Wake Forest University
| - |
H. Culp | M | 60 |
Wake Forest University
| - |
Eric Wiseman | M | 68 |
Wake Forest University
| - |
Matthew King | M | 65 |
Wake Forest University
| - |
Julia Gregory | F | 71 |
Iconic Therapeutics, Inc.
Iconic Therapeutics, Inc. BiotechnologyHealth Technology Iconic Therapeutics, Inc. engages in the development of novel therapeutics for the treatment of serious eye disorders. Its product ICON-1, is a novel immune-conjugate fusion protein that works with the body’s immune system to address the root causes of inflammation and angiogenesis together, potentially altering the course of causes of blindness. The company was founded by Alan Garen, Kirk Dornbush, and Michael I. Sherman in 2003 and is headquartered in South San Francisco, CA. | 7 años |
Scott E. Reed | M | 75 |
Wake Forest University
| - |
David W. Dupree | M | 71 |
Wake Forest University
| - |
Mark Leuchtenberger | M | 67 |
Wake Forest University
| - |
Ronald E. Deal | M | 80 |
Wake Forest University
| 21 años |
Todd Foley | M | 52 |
Iconic Therapeutics, Inc.
Iconic Therapeutics, Inc. BiotechnologyHealth Technology Iconic Therapeutics, Inc. engages in the development of novel therapeutics for the treatment of serious eye disorders. Its product ICON-1, is a novel immune-conjugate fusion protein that works with the body’s immune system to address the root causes of inflammation and angiogenesis together, potentially altering the course of causes of blindness. The company was founded by Alan Garen, Kirk Dornbush, and Michael I. Sherman in 2003 and is headquartered in South San Francisco, CA. | 10 años |
William L. Marks | M | 80 |
Wake Forest University
| - |
Curtis Farmer | M | 61 |
Wake Forest University
| - |
Bruce Robertson | M | 61 |
Iconic Therapeutics, Inc.
Iconic Therapeutics, Inc. BiotechnologyHealth Technology Iconic Therapeutics, Inc. engages in the development of novel therapeutics for the treatment of serious eye disorders. Its product ICON-1, is a novel immune-conjugate fusion protein that works with the body’s immune system to address the root causes of inflammation and angiogenesis together, potentially altering the course of causes of blindness. The company was founded by Alan Garen, Kirk Dornbush, and Michael I. Sherman in 2003 and is headquartered in South San Francisco, CA. | 10 años |
Dan Hicklin | M | 61 |
Maverick Therapeutics, Inc.
Maverick Therapeutics, Inc. BiotechnologyHealth Technology Maverick Therapeutics, Inc. operates as a preclinical stage biotech company. It develops a novel class of T cell- redirecting antibody therapeutics that have the potential to substantially broaden the range of targets and clinical applications to be used for this ultra-potent mechanism. The company was founded by Robert Dubridge and Patrick A. Baeuerle in 2016 and is headquartered in Brisbane, CA. | - |
Cantey M. Ergen | F | 68 |
Wake Forest University
| 5 años |
Adelaide Sink | F | 75 |
Wake Forest University
| - |
Andrew J. Schindler | M | 79 |
Wake Forest University
| - |
William G. Ward | M | 70 |
Wake Forest University
| - |
Thomas W. Bunn | M | 71 |
Wake Forest University
| 14 años |
Harold Rosser | M | 75 |
Wake Forest University
| - |
Daniel M. Delen | M | 58 |
Wake Forest University
| - |
Kim Westmoreland | M | - |
Wake Forest University
| - |
Charles Iacovou | M | - |
Wake Forest University
| - |
Elizabeth J. Gatewood | M | - |
Wake Forest University
| 20 años |
Stephen L. Wallenhaupt | M | - |
Wake Forest University
| - |
Peter Carlson | M | 60 |
Wake Forest University
| - |
Patrick Thean | M | - |
Wake Forest University
| - |
Ashish Khanna | M | 52 |
Fountain Therapeutics, Inc.
Fountain Therapeutics, Inc. BiotechnologyHealth Technology Fountain Therapeutics, Inc. develops treatment for aging-associated diseases. The company is headquartered in San Francisco, CA. | - |
Jack Lowden | M | 66 |
Wake Forest University
| - |
C. Nye | M | 61 |
Wake Forest University
| - |
Mitesh B. Shah | M | 54 |
Wake Forest University
| - |
Bruce A. Cohen | M | 71 |
Iconic Therapeutics, Inc.
Iconic Therapeutics, Inc. BiotechnologyHealth Technology Iconic Therapeutics, Inc. engages in the development of novel therapeutics for the treatment of serious eye disorders. Its product ICON-1, is a novel immune-conjugate fusion protein that works with the body’s immune system to address the root causes of inflammation and angiogenesis together, potentially altering the course of causes of blindness. The company was founded by Alan Garen, Kirk Dornbush, and Michael I. Sherman in 2003 and is headquartered in South San Francisco, CA. | - |
Lars Nelson | M | 65 |
Wake Forest University
| - |
K. Hirth | M | 72 |
Iconic Therapeutics, Inc.
Iconic Therapeutics, Inc. BiotechnologyHealth Technology Iconic Therapeutics, Inc. engages in the development of novel therapeutics for the treatment of serious eye disorders. Its product ICON-1, is a novel immune-conjugate fusion protein that works with the body’s immune system to address the root causes of inflammation and angiogenesis together, potentially altering the course of causes of blindness. The company was founded by Alan Garen, Kirk Dornbush, and Michael I. Sherman in 2003 and is headquartered in South San Francisco, CA. | 9 años |
Donald C. Ingram | M | - |
Wake Forest University
| - |
Andrew Liveris | M | 69 |
Hevolution Foundation
| - |
Evgeny Lebedev | M | - |
Hevolution Foundation
| - |
Gráfico relacional
Relaciones con varias empresas
Antiguas relaciones
Nombre | Sexo | Edad | Empresas relacionadas | Colaboración |
---|---|---|---|---|
Lori Kunkel | M | 66 |
Maverick Therapeutics, Inc.
Maverick Therapeutics, Inc. BiotechnologyHealth Technology Maverick Therapeutics, Inc. operates as a preclinical stage biotech company. It develops a novel class of T cell- redirecting antibody therapeutics that have the potential to substantially broaden the range of targets and clinical applications to be used for this ultra-potent mechanism. The company was founded by Robert Dubridge and Patrick A. Baeuerle in 2016 and is headquartered in Brisbane, CA. | 6 años |
Carl Johan Kördel | M | 62 |
Iconic Therapeutics, Inc.
Iconic Therapeutics, Inc. BiotechnologyHealth Technology Iconic Therapeutics, Inc. engages in the development of novel therapeutics for the treatment of serious eye disorders. Its product ICON-1, is a novel immune-conjugate fusion protein that works with the body’s immune system to address the root causes of inflammation and angiogenesis together, potentially altering the course of causes of blindness. The company was founded by Alan Garen, Kirk Dornbush, and Michael I. Sherman in 2003 and is headquartered in South San Francisco, CA. | - |
Kathryn Corzo | F | 63 |
Maverick Therapeutics, Inc.
Maverick Therapeutics, Inc. BiotechnologyHealth Technology Maverick Therapeutics, Inc. operates as a preclinical stage biotech company. It develops a novel class of T cell- redirecting antibody therapeutics that have the potential to substantially broaden the range of targets and clinical applications to be used for this ultra-potent mechanism. The company was founded by Robert Dubridge and Patrick A. Baeuerle in 2016 and is headquartered in Brisbane, CA. | 1 años |
Brandon Smith | M | 50 |
Iconic Therapeutics, Inc.
Iconic Therapeutics, Inc. BiotechnologyHealth Technology Iconic Therapeutics, Inc. engages in the development of novel therapeutics for the treatment of serious eye disorders. Its product ICON-1, is a novel immune-conjugate fusion protein that works with the body’s immune system to address the root causes of inflammation and angiogenesis together, potentially altering the course of causes of blindness. The company was founded by Alan Garen, Kirk Dornbush, and Michael I. Sherman in 2003 and is headquartered in South San Francisco, CA. | 3 años |
Estadísticas
País | Relaciones | % del total |
---|---|---|
Estados Unidos | 68 | 83.95% |
Arabia Saudita | 13 | 16.05% |
Antigüedad de la relación
Activas
Pasados
Hombre
Mujer
Administradores
Ejecutivos
Origen de las relaciones
- Bolsa de valores
- Insiders
- William Greene
- Red Personal